Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE.
For Glycaemic Control and Reduction of risk of cardiovascular death, patients with severe renal impairment (eGFR less than 30mL/min/1.73m2), end-stage renal disease and patients on dialysis. The efficacy of JARDIANCE is dependent on renal function (see Precautions).
For treatment of heart failure in patients with or without type 2 diabetes mellitus, JARDIANCE 10 mg is not recommended in patients with eGFR <20 ml/min/1.73m2 or CrCl <20 ml/min.
In case of rare hereditary conditions that may be incompatible with an excipient of the product, the use of the product is contraindicated. The JARDIANCE 10 mg tablet contains 162.5 mg of lactose monohydrate and the JARDIANCE 25 mg tablet contains 113 mg of lactose monohydrate per tablet. Patients with the rare hereditary conditions of galactose intolerance e.g. galactosaemia should not take this medicine.